The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), ...

ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a ...

ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced ...

Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Alimera Sciences Inc (ALIM) stock saw a modest uptick, ending the day at $5.53 which represents a slight increase of $0.34 or 6.55% from the prior close of $5.19. The stock opened at $5.53 and touched ...

ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an ...

Mr Kim called for the site to increase its production of nuclear warheads, state media said. Brazil and Argentina are both defeated in their latest qualifying matches for the 2026 Fifa World Cup ...

Alimera Sciences files lawsuit against ANI Pharmaceuticals over failed merger, causing stock to plummet 25% in premarket ...

Alimera Sciences, Inc. (ALIM), a biopharmaceutical company, announced on Tuesday that it has filed a lawsuit in the Delaware Court of ...